Jan 27, 04
|
| 07:00 ET |
Esperion Receives Fifth U.S. Patent for Small Molecule Program
|
|
Jan 22, 04
|
| 16:03 ET |
Esperion Reports Financial Results for the Quarter and Year Ended December 31, 2003
|
|
Jan 13, 04
|
| 07:00 ET |
Esperion Announces License Agreement With Nippon Chemiphar To Develop New Therapies Based on PPAR Delta Agonists
|
|
Jan 09, 04
|
| 11:55 ET |
Esperion to Present at JPMorgan Healthcare Conference
|
|
Jan 08, 04
|
| 09:03 ET |
Esperion Announces Settlement of Short-Swing Profit Lawsuit
|
|
Dec 16, 03
|
| 08:01 ET |
Esperion Reports Positive Results for Second Phase 1 Study of ETC-642
|
|
Dec 04, 03
|
| 08:00 ET |
Esperion Announces Positive Results of Phase 1 Study of ETC-1001
|
|
Nov 10, 03
|
| 17:01 ET |
Esperion to Present at the CIBC World Markets Healthcare Conference
|
|
Nov 04, 03
|
| 16:00 ET |
Esperion Announces Publication of Results From Phase 2 Study of ETC-216 and Upcoming Conference Call
|
|
Nov 03, 03
|
| 21:19 ET |
Esperion to Hold Conference Call to Provide Update On Findings From Study of ETC-216
|
|
Oct 20, 03
|
| 16:01 ET |
Esperion Reports Financial Results for the Quarter And Nine Months Ended September 30, 2003
|
|
Oct 17, 03
|
| 16:31 ET |
Esperion to Present at Rodman & Renshaw Techvest Healthcare Conference
|
|
Oct 13, 03
|
| 16:01 ET |
Results of Phase 1 Study of ETC-642 to be Presented at American Heart Association Scientific Sessions
|
|
Sep 22, 03
|
| 08:48 ET |
Esperion to Present at UBS Global Life Sciences Conference On September 25, 2003
|
|
Aug 29, 03
|
| 12:34 ET |
Esperion to Present at NewsMakers in the Biotech Industry Conference on September 4, 2003
|
|
Aug 25, 03
|
| 16:00 ET |
Esperion Files Suit to Recover Profits From Short-Swing Transactions
|
|
Aug 18, 03
|
| 16:35 ET |
Eleventh U.S. Patent Issued for Esperion's RLT Peptide Program
|
|
Jul 31, 03
|
| 19:24 ET |
Esperion Announces Pricing of Public Offering of Common Stock
|
|
Jul 30, 03
|
| 17:34 ET |
Esperion Statement Regarding Largest Stockholder
|
|
Jul 24, 03
|
| 17:27 ET |
Esperion Initiates Phase I Study of ETC-1001
|
|
Jul 16, 03
|
| 16:03 ET |
Esperion Reports Financial Results for the Quarter And Six Months Ended June 30, 2003
|
|
Jul 11, 03
|
| 17:58 ET |
Esperion Files Registration Statement For Public Offering
|
|
Jun 30, 03
|
| 10:26 ET |
Esperion Begins Multiple-Dose Study of ETC-642 (RLT Peptide) In Patients with Stable Atherosclerosis
|
|
Jun 26, 03
|
| 07:01 ET |
Regression of Atherosclerosis Seen with ETC-216 (AIM)
|
|
Jun 05, 03
|
| 08:15 ET |
Adeoye Olukotun, M.D., M.P.H., F.A.C.C., Joins Esperion as Senior Vice President of Clinical and Regulatory Affairs and Chief Medical Officer
|
|
Apr 17, 03
|
| 16:07 ET |
Esperion Reports Financial Results for the Quarter Ended March 31, 2003
|
|
Mar 24, 03
|
| 14:37 ET |
Esperion Presents Special Webcast Update on Recent Trends in Lipid Regulating Therapy From Dr. Antonio M. Gotto, Jr. of Weill Medical College
|
|
Mar 05, 03
|
| 13:34 ET |
Esperion Receives Third U.S. Patent for Oral Small Molecule Program
|
|
Jan 27, 03
|
| 16:07 ET |
Esperion Reports Financial Results For the Fourth Quarter And Year Ended December 31, 2002
|
|
Dec 12, 02
|
| 06:45 ET |
Esperion Initiates Multiple-Dose LUV (ETC-588) Phase II Clinical Trial in Patients with Acute Coronary Syndromes
|
|
Oct 24, 02
|
| 07:47 ET |
Esperion Reports Financial Results for the Third Quarter And Nine-Months Ended September 30, 2002
|
|
Sep 18, 02
|
| 11:34 ET |
Esperion Begins Second Clinical Study of RLT Peptide (ETC-642) in Patients
|
|